Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phase 3 trial.
Tsutomu TakeuchiYoshiya TanakaSatoshi SoenHisashi YamanakaToshiyuki YonedaSakae TanakaTakaya NittaNaoki OkuboHarry K GenantDésirée Mfm van der HeijdePublished in: Annals of the rheumatic diseases (2019)
Denosumab inhibits the progression of joint destruction, increases BMD and is well tolerated in patients with RA taking csDMARD.
Keyphrases
- placebo controlled
- double blind
- clinical trial
- rheumatoid arthritis
- bone mineral density
- study protocol
- phase iii
- phase ii
- giant cell
- phase ii study
- open label
- randomized controlled trial
- postmenopausal women
- body composition
- radiation therapy
- idiopathic pulmonary fibrosis
- newly diagnosed
- systemic lupus erythematosus